Vanguard Group Inc. Has $4.94 Billion Holdings in Cencora, Inc. (NYSE:COR)

Vanguard Group Inc. decreased its position in Cencora, Inc. (NYSE:COR) by 0.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,348,522 shares of the company’s stock after selling 162,277 shares during the period. Vanguard Group Inc. owned approximately 10.20% of Cencora worth $4,944,487,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. acquired a new stake in Cencora during the first quarter worth approximately $1,199,695,000. Bank of New York Mellon Corp bought a new position in Cencora during the first quarter worth $291,825,000. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in Cencora in the first quarter valued at $238,457,000. Coho Partners Ltd. acquired a new position in shares of Cencora during the first quarter valued at about $206,194,000. Finally, Mawer Investment Management Ltd. acquired a new stake in shares of Cencora in the 1st quarter valued at about $191,309,000. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR stock traded down $0.11 during trading hours on Friday, hitting $223.60. 1,357,117 shares of the company were exchanged, compared to its average volume of 1,543,746. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41. The stock has a market capitalization of $44.60 billion, a price-to-earnings ratio of 24.46, a P/E/G ratio of 1.55 and a beta of 0.45. The firm has a fifty day simple moving average of $226.58 and a 200 day simple moving average of $230.09. Cencora, Inc. has a 52-week low of $171.65 and a 52-week high of $246.75.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The business had revenue of $68.41 billion during the quarter, compared to the consensus estimate of $70.60 billion. During the same period last year, the business posted $3.50 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Research analysts predict that Cencora, Inc. will post 13.46 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were issued a dividend of $0.51 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.91%. Cencora’s payout ratio is 22.32%.

Insiders Place Their Bets

In related news, CEO Steven H. Collis sold 10,755 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dermot Mark Durcan purchased 500 shares of the firm’s stock in a transaction dated Friday, May 24th. The stock was purchased at an average cost of $218.58 per share, for a total transaction of $109,290.00. Following the acquisition, the director now owns 21,876 shares of the company’s stock, valued at approximately $4,781,656.08. The disclosure for this purchase can be found here. Insiders have sold a total of 1,899,112 shares of company stock worth $408,654,376 over the last 90 days. Corporate insiders own 15.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Citigroup increased their price target on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Robert W. Baird upped their price objective on shares of Cencora from $280.00 to $285.00 and gave the stock an “outperform” rating in a report on Tuesday, July 9th. SVB Leerink restated an “outperform” rating and issued a $275.00 target price on shares of Cencora in a report on Thursday, June 27th. Finally, StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $238.78.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.